Dose response in the tetrazolium test for skin carcinogenicity.

The tetrazolium test for skin carcinogenicity was performed with different doses of (i) a strong, complete carcinogen with moderate cytotoxicity, 20-methylcholanthrene; (ii) a weak carcinogen with strong cytotoxicity, the promoter 12-O-tetradecanoylphorbol-13-acetate; (iii) a strong toxic substance...

Descripción completa

Detalles Bibliográficos
Autor principal: Iversen, O. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1980
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010254/
https://www.ncbi.nlm.nih.gov/pubmed/7190018
_version_ 1782136283127087104
author Iversen, O. H.
author_facet Iversen, O. H.
author_sort Iversen, O. H.
collection PubMed
description The tetrazolium test for skin carcinogenicity was performed with different doses of (i) a strong, complete carcinogen with moderate cytotoxicity, 20-methylcholanthrene; (ii) a weak carcinogen with strong cytotoxicity, the promoter 12-O-tetradecanoylphorbol-13-acetate; (iii) a strong toxic substance with very weak carcinogenicity for the skin, cantharidin; and (iv) X-rays. The dose-response relationship was determined, and the validity of the tetrazolium test was confirmed. However, substances strongly cytotoxic must be tested in small doses to avoid necrosis. The tetrazolium test should not be used on the skin to test substances carcinogenic for organs other than skin.
format Text
id pubmed-2010254
institution National Center for Biotechnology Information
language English
publishDate 1980
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20102542009-09-10 Dose response in the tetrazolium test for skin carcinogenicity. Iversen, O. H. Br J Cancer Research Article The tetrazolium test for skin carcinogenicity was performed with different doses of (i) a strong, complete carcinogen with moderate cytotoxicity, 20-methylcholanthrene; (ii) a weak carcinogen with strong cytotoxicity, the promoter 12-O-tetradecanoylphorbol-13-acetate; (iii) a strong toxic substance with very weak carcinogenicity for the skin, cantharidin; and (iv) X-rays. The dose-response relationship was determined, and the validity of the tetrazolium test was confirmed. However, substances strongly cytotoxic must be tested in small doses to avoid necrosis. The tetrazolium test should not be used on the skin to test substances carcinogenic for organs other than skin. Nature Publishing Group 1980-03 /pmc/articles/PMC2010254/ /pubmed/7190018 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Iversen, O. H.
Dose response in the tetrazolium test for skin carcinogenicity.
title Dose response in the tetrazolium test for skin carcinogenicity.
title_full Dose response in the tetrazolium test for skin carcinogenicity.
title_fullStr Dose response in the tetrazolium test for skin carcinogenicity.
title_full_unstemmed Dose response in the tetrazolium test for skin carcinogenicity.
title_short Dose response in the tetrazolium test for skin carcinogenicity.
title_sort dose response in the tetrazolium test for skin carcinogenicity.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010254/
https://www.ncbi.nlm.nih.gov/pubmed/7190018
work_keys_str_mv AT iversenoh doseresponseinthetetrazoliumtestforskincarcinogenicity

Ejemplares similares